IIM
SRPT icon

INTECH Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

INTECH Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76M Buy
153,518
+110,661
+258% +$2.09M 0.03% 587
2026
Q1 		$933K Buy
+42,857
New +$829K 0.01% 1045
2023
Q4 		– Sell
-6,175
Closed -$749K – 747
2023
Q3 		$749K Buy
+6,175
New +$698K 0.01% 502
2022
Q4 		– Sell
-5,756
Closed -$636K – 677
2022
Q3 		$636K Buy
+5,756
New +$580K ﹤0.01% 564

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

INTECH Investment Management's SRPT Position: Q2 2026 in Review

INTECH Investment Management increased its Sarepta Therapeutics (SRPT) stake by 258% in Q2 2026, buying an estimated $2.09M and bringing the position to 153,518 shares worth $2.76M. The position accounts for 0.03% of the portfolio, ranked #587.

INTECH Investment Management first reported a position in SRPT in Q3 2022 and has held it in 4 quarters since. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • INTECH Investment Management held 153,518 shares of Sarepta Therapeutics worth $2.76M as of Q2 2026.
  • INTECH Investment Management bought 110,661 Sarepta Therapeutics shares in Q2 2026, an estimated $2.09M.
  • Sarepta Therapeutics made up 0.03% of INTECH Investment Management's portfolio in Q2 2026, its #587 holding.
  • INTECH Investment Management first reported a position in Sarepta Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.